Synthesis and α1-antagonist activity of new prazosin- and benextramine-related tetraamine disulfides

European Journal of Medicinal Chemistry

Volumn 32, Issue 1, 1997, Pages 9-20

  Giardina D ^a   Crucianelli, M ^a   Gulini, U ^a   Marucci, G ^a   Melchiorre, C ^b   Spampinato, S ^b  

^a UNIVERSITY OF CAMERINO   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Benextramine; Diaminoquinazoline; Prazosin; Tetraamine disulfide; Adrenoceptor antagonist; 1 Adrenoceptor subtype affinity

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BENEXTRAMINE; CLONIDINE; NORADRENALIN; PRAZOSIN;

ANIMAL TISSUE; ARTICLE; BINDING SITE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; RAT; RECEPTOR AFFINITY; SUBMANDIBULAR GLAND; VAS DEFERENS;

EID: 0031036714     PISSN: 02235234     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0223-5234(97)84357-7     Document Type: Article

References (50)

1. 1 Bylund DB, Eikenberg DC, Hieble JP et al (1994) Pharmacol Rev 46, 121-136
2. 2 Hieble JP, Bylund DB, Clarke DE et al (1995) Pharmacol Rev 47, 267-270
3. 3 Hieble JP, Bondinell WE, Ruffolo RR Jr (1995) J Med Chem 38, 3415-3444
4. 4 Goetz AS, King HK, Ward SDC et al (1995) Eur J Pharmacol 272, R5-R6
5. 5 Michel AD, Loury DN, Whiting RL (1989) Br J Pharmacol 98, 883-889
6. 6 García-Sáinz JA, Romero-Avila MaT, Tórres-Márquez MaE (1995) Eur J Pharmacol-Mol Pharmacol Section 289, 81-86
7. 7 Eltze M, Boer R, Sanders KH, Kolassa N (1991) Eur J Pharmacol 202, 33-44
8. 8 Testa R, Guarneri L, Ibba M et al (1993) Eur J Pharmacol 249, 307-315
9. 9 Han C, Abel PW, Minneman KP (1987) Nature 329, 333-335
10. 10 Aboud R, Shafii M, Docherty Jr (1993) Br J Pharmacol 109, 80-87
11. 11 Testa R, Guarneri L, Poggesi E, Simonazzi I, Taddei C, Leonardi A (1995) Br J Pharmacol 114, 745-750
12. 12 Cotecchia S, Schwinn DA, Randall RR et al (1988) Proc Natl Acad Sci USA 85, 7159-7163
13. 13 Schwinn DA, Lomasney JW, Lowry P et al (1990) J Biol Chem 265, 8183-8189
14. 14 Lomasney JW, Cotecchia S, Lorenz W et al (1991) J Biol Chem 266, 6365-6369
15. 15 Perez DM, Piascik MT, Graham RM (1991) Mol Pharmacol 40, 876-883
16. 16 Pimoule C, Langer SZ, Graham D (1995) Eur J Pharmacol 290, 49-53
17. 17 Faure C, Pimoule C, Arbilla S, Langer SZ, Graham D (1994) Eur J Pharmacol-Mol Pharmacol Section 268, 141-149
18. 18 Ford APDW, Williams TJ, Blue DR, Clarke DE (1994) Trends in Pharmacol Sci 15, 167-170
19. 19 Melchiorre C (1981) Trends in Pharmacol Sci 2, 209-211
20. 20 Melchiorre C, Recanatini M, Bolognesi ML, Filippi P, Minarini A (1993) Current Topics in Med Chem 1, 43-65
21. 21 Lippert B, Belleau B (1973) In: Frontiers in Catecholamine Research (Usdin E, Snyder SH, eds) Pergamon, New York, 369-371
22. 22 Melchiorre C, Yong MS, Benfey BG, Belleau B (1978) J Med Chem 21, 1126-1132
23. 23 Cavero I, Roach AG (1980) Life Sci 27, 1525-1540
24. 24 Langer SZ, Cavero I, Massingham R (1980) Hypertension (Dallas) 2, 372-382
25. 25 Colucci WS (1982) Ann Intern Med 97, 67-77
26. 26 Davey MJ (1980) J Cardiovasc Pharmacol 2, 287-301
27. 27 Lund-Johansen P, Hjermann I, Iversen BM, Thaulow E (1993) Cardiology 83, 150-159
28. 28 Melchiorre C, Giannella M, Brasili L, Benfey BG, Belleau B (1981) Eur J Med Chem 16, 111-114
29. 29 Alvarez M, Granados R, Mauleon D et al (1987) J Med Chem 30, 1186-1193
30. 30 Campbell SF, Davey MJ, Hardstone JD, Lewis BN, Palmer MJ (1987) J Med Chem 30, 49-57
31. 31 Sallès J, Badia A (1994) Eur J Pharmacol-Mol Pharmacol Sect 266, 301-308
32. 32 Giardinà D, Gulini U, Massi M et al (1993) J Med Chem 36, 690-698
33. 33 Althuis TH, Hess HJ (1977) J Med Chem 20, 146-149
34. 34 Melchiorre C, Giardinà D, Angeli P (1980) J Heterocycl Chem 17, 1215-1216
35. 35 Wineman RJ, Gollis MH, James JC, Pomponi AM (1962) J Org Chem 4222-4226
36. 36 Gollis MH, Wineman RJ, James JC (1967) US Patent 3,312,732; Chem Abstr 67, P11342x
37. 37 Ribes F, Guglielmetti R, Metzger J (1972) Bull Soc Chim Fr 1, 143-147
38. 38 Motawia MS, Wengel J, Abdel-Megio AES, Pedersen EB (1989) Synthesis 384-387
39. 39 McGrath JC (1978) J Physiol (Lond) 283, 23-39
40. 40 Brown CM, McGrath JC, Summers RJ (1979) Br J Pharmacol 66, 553-564
41. 41 Arunlakshana D, Schild HO (1959) Br J Pharmacol 14, 48-58
42. 42 Cheng YC, Prusoff WH (1973) Biochem Pharmacol 22, 3099-3108
43. 43 Munson PJ, Rodbard D (1980) Anal Biochem 107, 220-239
44. 44 Tallarida RJ, Cowan A, Adler MW (1979) Life Sci 25, 637-654
45. 45 Giardinà D, Crucianelli M, Melchiorre C, Taddei C, Testa R (1995) Eur J Pharmacol 287, 13-16
46. 46 Furchgott RF (1972) In: Cathecolamines-Handbook of Experimental Pharmacology (Blanschko H, Muscholl E, eds) Springer, Berlin, 33, 283-335
47. 47 Drew GM (1977) Eur J Pharmacol 42, 123-130
48. 48 Doxey JC, Smith CFC, Walker JM (1977) Br J Pharmacol 60, 91-96
49. 49 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) J Biol Chem 193, 265-275
50. 50 Scatchard G (1949) Ann NY Acad Sci 51, 600-672